Integrins, a family of heterodimeric adhesion receptors for various extracellular matrices, have repeatedly been linked to being important initiators and promoters of ovarian cancer growth and progression. Aggressive ovarian tumors exhibit significantly elevated levels of several RGD-based integrin family members, including integrins 5-1 and v3 or v5. These adhesion receptors appear to encourage cell adhesion, survival, motility, and invasion during the development of an ovarian tumor or the spread of its metastatic disease. Notably, the activation of FAK and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways, is crucial for the functions of these integrins.
Transmembrane proteins called integrins serve as important receptors for cell-extracellular matrix (ECM) and cell-cell adhesion.These molecules can be modified, and the v integrin family in particular, has shown to have significant effects on fibrosis in a variety of organs and disease states. According to numerous studies, the latent transforming growth factor (TGF)- is activated by the integrins v3, v5, v6, and v8 in pre-clinical fibrosis models, modulating the fibrotic process.
One of the 18 different types of subunits that are known to exist and one of the eight different types of subunits that are known to exist are typically non-covalently paired to form each integrin. There are currently 24 different heterodimers in total. The fact that the v subunit can form heterodimers with the 1, 3, 5, 6 or 8 subunits and that the 1 subunit can associate with a wide variety of subunits from 1 to 11 shows that not all theoretically possible and subunit pairs form. It's intriguing to note that a variety of v integrins appear to share a common function in TGF- activation.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4970 | Cucurbitacin B | 6199-67-3 | Cucurbitacin B, a naturally occurring triterpene analog and a potential cancer chemotherapeutic agent, could repress cancer cell progression. |
|
V2992 | CWHM-12 | 1564286-55-0 | CWHM-12 isa novel potent small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8. |
|
V1601 | Cyclo(-RGDfK) | 161552-03-0 | Cyclo(-RGDfK) is a potent, selective and cyclo-peptide-based αvβ3 integrin inhibitor with potential antitumor activity. |
|
V52210 | Cyclo(-RGDfK) TFA | 500577-51-5 | Cyclo(-RGDfK) TFA is a potent and specific inhibitor of integrin αvβ3 with IC50 of 0.94 nM. |
|
V56055 | Cyclo(Ala-Arg-Gly-Asp-Mamb) (XJ735) | 153381-95-4 | Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist that may be utilized in research on the treatment of pulmonary arterial hypertension. |
|
V52209 | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo(RGDfC)) | 862772-11-0 | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) is a cyclic RGD peptide with high affinity for αvβ3 that disrupts cellular integrin interactions. |
|
V77117 | Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (Cyclo(RGDfC) TFA) | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA is a cyclic RGD peptide with high affinity for αvβ3 that disrupts cellular integrin interactions. | |
|
V56052 | Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) | 135432-37-0 | Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. |
|
V52206 | Cyclo(RGDyK) | 217099-14-4 | Cyclo(RGDyK) is a potent and specific αVβ3 integrin inhibitor (antagonist) with IC50 of 20 nM. |
|
V1602 | Cyclo(RGDyK) TFA | 250612-42-1 | Cyclo(RGDyK) TFA, the trifluoroacetate (TFA) salt of Cyclo(RGDyK) which isa glycosylated RGD-containing peptide (RGD-peptide), is a potent and selective αVβ3 integrin inhibitor with potential antineoplastic activity. |
|
V56047 | Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10) | 166184-23-2 | Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10), a decapeptide containing a cyclic RGD active sequence, is an integrin (Integrin) αIIbβ3 antagonist. |
|
V78978 | Cys-αvβ6-BP | Cys-αvβ6-BP is a cysteine-terminated αvβ6-binding peptide. | |
|
V78979 | Cys-αvβ6-BP TFA | Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6-binding peptide. | |
|
V56057 | Echistatin | 154303-05-6 | Echistatin is originally the smallest RGD active protein from the vexin family and is a potent inhibitor of platelet aggregation. |
|
V77051 | Echistatin TFA | Echistatin TFA is originally the smallest RGD active protein from the echistatin family and is a potent inhibitor of platelet aggregation. | |
|
V52141 | Efalizumab | 214745-43-4 | Efalizumab is a modulator targeting T cells and is a humanized monoclonal antibody (mAb) against the LFA-1 alpha subunit CD11a. |
|
V79250 | Egaptivon pegol sodium (ARC 1779 sodium) | Egaptivon pegol sodium is a nucleic acid aptamer that blocks the binding of von Willebrand Factor (VWF) to platelet GPIb receptors. | |
|
V56058 | EILEVPST | 239075-62-8 | EILEVST is a recombinant human fibronectin-derived low molecular weight peptide fragment. |
|
V52131 | EMD527040 | 851333-14-7 | EMD527040 is a potent and selective αvβ6 antagonist (inhibitor) with antifibrotic activity. |
|
V19321 | Enlimomab (BI-RR 0001; Anti-Human IL6 Recombinant Antibody) | 142864-19-5 | Enlimomab (BI-RR 0001) is a mouse IgG2a monoclonal antibody (mAb) directed against human ICAM-1, which inhibits leukocyte adhesion to the vascular endothelium, thereby reducing leukocyte extravasation and inflammatory tissue damage. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
